ALKERMES PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.91 USD | -1.03% |
|
+2.18% | -13.81% |
| 05-23 | Cantor Fitzgerald Adjusts Alkermes Price Target to $48 From $43, Maintains Overweight Rating | MT |
| 05-02 | UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 4.05B | ||||||
| 57.87B | - | |||||
| 40.25B | ||||||
| 39.94B | ||||||
| 28.54B | ||||||
| 26.4B |
- Stock Market
- Equities
- ALKS Stock
- Charts Alkermes plc
- Sector Chart
